Close Menu

NEW YORK (GenomeWeb News) – CellAura will provide its fluorescent reagents to Cisbio Bioassays for use with its non-radioactive assays for cellular studies, CellAura said today.

Under the agreement, CellAura will develop a number of reagents for Cisbio's Tag-lite platform, which is used for studies of cell surface receptor dimerization and ligand binding.

CellAura, a spin-out from the University of Nottingham, will retain the rights for the reagents developed for use in its own range of assays for certain markets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.